Blueprint
FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
Report of Foreign Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For
period ending 16 December 2016
GlaxoSmithKline plc
(Name
of registrant)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or
will
file annual reports under cover Form 20-F or Form 40-F
Form
20-F x Form 40-F
--
Indicate
by check mark whether the registrant by furnishing the
information
contained in this Form is also thereby furnishing the
information
to the Commission pursuant to Rule 12g3-2(b) under the
Securities
Exchange Act of 1934.
GlaxoSmithKline
plc
(the 'Company')
Notification of Transfer of Shares out of Treasury
Pursuant
to the Financial Conduct Authority's Listing Rule 12.6.4, the
Company hereby notifies the market of the following:
On 15
December 2016, the Company transferred 33,300,000 ordinary shares
of 25 pence each ('Ordinary Shares') that were held by the Company
in treasury ('Treasury Shares') to the GlaxoSmithKline Employee
Benefit Trust to be used specifically to satisfy awards granted
under the Company's Deferred Annual Bonus Plan, Performance Share
Plan and Share Value Plan. The consideration received was
£15.07 pence per Ordinary Share.
Following
the transfer, the Company's issued share capital consisted of
5,368,238,025 Ordinary Shares, of which
458,205,950 were held as
Treasury Shares.
Therefore,
the total number of voting rights in the Company is 4,910,032,075.
This figure may be used by shareholders as the denominator for the
calculations by which they will determine if they are required to
notify their interest in, or a change to their interest in, the
Company under the Financial Conduct Authority's Disclosure and
Transparency Rules.
V A Whyte
Company Secretary
16
December 2016
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorised.
|
|
GlaxoSmithKline plc
|
|
|
(Registrant)
|
|
|
|
|
Date: December
16, 2016
|
|
|
|
|
|
|
By: VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GlaxoSmithKline plc
|